(PDF) Pcn133 - The Societal Impact of Obinutuzumab in the

Pcn133 - The Societal Impact of Obinutuzumab in the First Line Treatment of Patients With Follicular Lymphoma in Germany

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.216

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Management of Patients With Follicular Lymphoma Treated First Line With Obinutuzumab

Asia-Pacific Journal of Clinical Oncology

English

Recent Advances in the First-Line Treatment of Follicular Non-Hodgkin Lymphoma

Molecular Biology

English

Pcn83 - The Use of Obinutuzumab in Treatment of Refractory and Relapsing Follicular Lymphoma

Value in Health

Occupational Health

English

Pcn141 - Cost-Effectiveness Analysis of Obinutuzumab for the Treatment of Patients With Previously Untreated Advanced Follicular Lymphoma in Greece

Value in Health

Occupational Health

English

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Hematological Oncology

Cancer Research

English

Impact of Treatment in Long-Term Survival Patients With Follicular Lymphoma: A Spanish Lymphoma Oncology Group Registry

Multidisciplinary

English

M7‐FLIPI Is Not Prognostic in Follicular Lymphoma Patients With First‐line Rituximab Chemo‐free Therapy

British Journal of Haematology

English

Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Hematological Oncology

Cancer Research

English

The Impact of First Complete Remission by PET-CT and Time to Next Treatment on Survival of Follicular Lymphoma Patients

Clinical Hematology International

English